- Home
- STEW vs IMCR Comparison
STEW vs IMCR Comparison
Compare STEW & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STEW
- IMCR
- Stock Information
- Founded
- STEW 1972
- IMCR 2008
- Country
- STEW United States
- IMCR United Kingdom
- Employees
- STEW N/A
- IMCR N/A
- Industry
- STEW Investment Managers
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STEW Finance
- IMCR Health Care
- Exchange
- STEW Nasdaq
- IMCR Nasdaq
- Market Cap
- STEW 1.8B
- IMCR 1.7B
- IPO Year
- STEW N/A
- IMCR 2021
- Fundamental
- Price
- STEW $17.70
- IMCR $33.46
- Analyst Decision
- STEW
- IMCR Buy
- Analyst Count
- STEW 0
- IMCR 9
- Target Price
- STEW N/A
- IMCR $62.38
- AVG Volume (30 Days)
- STEW 84.5K
- IMCR 358.1K
- Earning Date
- STEW 01-01-0001
- IMCR 11-06-2025
- Dividend Yield
- STEW 3.71%
- IMCR N/A
- EPS Growth
- STEW N/A
- IMCR N/A
- EPS
- STEW 1.44
- IMCR N/A
- Revenue
- STEW N/A
- IMCR $356,145,000.00
- Revenue This Year
- STEW N/A
- IMCR $29.99
- Revenue Next Year
- STEW N/A
- IMCR $8.85
- P/E Ratio
- STEW $10.34
- IMCR N/A
- Revenue Growth
- STEW N/A
- IMCR 26.78
- 52 Week Low
- STEW $11.97
- IMCR $23.15
- 52 Week High
- STEW $14.94
- IMCR $39.33
- Technical
- Relative Strength Index (RSI)
- STEW 44.59
- IMCR 50.64
- Support Level
- STEW $17.66
- IMCR $31.36
- Resistance Level
- STEW $17.93
- IMCR $34.11
- Average True Range (ATR)
- STEW 0.18
- IMCR 1.39
- MACD
- STEW -0.01
- IMCR -0.04
- Stochastic Oscillator
- STEW 42.98
- IMCR 63.90
About STEW SRH Total Return Fund Inc.
SRH Total Return Fund, Inc. is a non-diversified closed-end management investment company. The company's investment objective is to seek total returns. Its fund utilizes a bottom-up, value-driven investment process to identify securities of good quality businesses trading below estimated intrinsic value. The Funds are available as an actively-managed closed-end fund, an actively managed ETF and a passively-managed ETF.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.